التفاصيل البيبلوغرافية
| العنوان: |
c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2. |
| المؤلفون: |
Su, Min-Xia, Xu, Yu-Lian, Jiang, Xiao-Ming, Huang, Mu-Yang, Zhang, Le-Le, Yuan, Luo-Wei, Xu, Xiao-Huang, Zhu, Qi, Gao, Jian-Li, Lu, Jia-Hong, Chen, Xiuping, Huang, Ming-Qing, Wang, Yitao, Lu, Jin-Jian |
| المصدر: |
Acta Pharmaceutica Sinica B; Mar2022, Vol. 12 Issue 3, p1240-1253, 14p |
| مصطلحات موضوعية: |
GINSENOSIDES, EVEROLIMUS, ANTINEOPLASTIC agents, GINSENG, MTOR inhibitors, LUNG cancer |
| مستخلص: |
The mammalian target of rapamycin (mTOR) pathway is abnormally activated in lung cancer. However, the anti-lung cancer effect of mTOR inhibitors as monotherapy is modest. Here, we identified that ginsenoside Rh2, an active component of Panax ginseng C. A. Mey., enhanced the anti-cancer effect of the mTOR inhibitor everolimus both in vitro and in vivo. Moreover, ginsenoside Rh2 alleviated the hepatic fat accumulation caused by everolimus in xenograft nude mice models. The combination of everolimus and ginsenoside Rh2 (labeled Eve-Rh2) induced caspase-independent cell death and cytoplasmic vacuolation in lung cancer cells, indicating that Eve-Rh2 prevented tumor progression by triggering paraptosis. Eve-Rh2 up-regulated the expression of c-MYC in cancer cells as well as tumor tissues. The increased c-MYC mediated the accumulation of tribbles homolog 3 (TRIB3)/P62+ aggresomes and consequently triggered paraptosis, bypassing the classical c-MYC/MAX pathway. Our study offers a potential effective and safe strategy for the treatment of lung cancer. Moreover, we have identified a new mechanism of TRIB3/P62+ aggresomes-triggered paraptosis and revealed a unique function of c-MYC. Eve-Rh2 up-regulates the expression of c-MYC, which mediates the accumulation of TRIB3/P62+ aggresomes bypassing the classical c-MYC/MAX pathway, thereby triggering paraptosis and ultimately inhibiting tumor progression. [Display omitted] [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Pharmaceutica Sinica B is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder